370 related articles for article (PubMed ID: 28594458)
1. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.
Waters EK; Sigh J; Friedrich U; Hilden I; Sørensen BB
Haemophilia; 2017 Sep; 23(5):769-776. PubMed ID: 28594458
[TBL] [Abstract][Full Text] [Related]
2. Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.
Eichler H; Angchaisuksiri P; Kavakli K; Knoebl P; Windyga J; Jiménez-Yuste V; Harder Delff P; Chowdary P
Haemophilia; 2019 Jan; 25(1):60-66. PubMed ID: 30408848
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients.
Chelle P; Montmartin A; Damien P; Piot M; Cournil M; Lienhart A; Genre-Volot F; Chambost H; Morin C; Tardy-Poncet B
Haemophilia; 2019 Mar; 25(2):343-348. PubMed ID: 30690836
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Chowdary P
Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
Chowdary P; Lethagen S; Friedrich U; Brand B; Hay C; Abdul Karim F; Klamroth R; Knoebl P; Laffan M; Mahlangu J; Miesbach W; Dalsgaard Nielsen J; Martín-Salces M; Angchaisuksiri P
J Thromb Haemost; 2015 May; 13(5):743-54. PubMed ID: 25641556
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.
Eichler H; Angchaisuksiri P; Kavakli K; Knoebl P; Windyga J; Jiménez-Yuste V; Hyseni A; Friedrich U; Chowdary P
J Thromb Haemost; 2018 Nov; 16(11):2184-2195. PubMed ID: 30137664
[TBL] [Abstract][Full Text] [Related]
7. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
Fernández-Bello I; Stenmo C; Butta N; Lind V; Ezban M; Jiménez-Yuste V
Haemophilia; 2017 Nov; 23(6):868-876. PubMed ID: 28851065
[TBL] [Abstract][Full Text] [Related]
9. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas.
Patel-Hett S; Martin EJ; Mohammed BM; Rakhe S; Sun P; Barrett JC; Nolte ME; Kuhn J; Pittman DD; Murphy JE; Brophy DF
Haemophilia; 2019 Sep; 25(5):797-806. PubMed ID: 31336410
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.
Agersø H; Overgaard RV; Petersen MB; Hansen L; Hermit MB; Sørensen MH; Petersen LC; Hilden I
Eur J Pharm Sci; 2014 Jun; 56():65-9. PubMed ID: 24568891
[TBL] [Abstract][Full Text] [Related]
11. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
12. Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A.
van Veen JJ; Gatt A; Bowyer AE; Cooper PC; Kitchen S; Makris M
Thromb Res; 2009 Apr; 123(6):895-901. PubMed ID: 19012951
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.
Hansson KM; Gustafsson D; Skärby T; Frison L; Berntorp E
J Thromb Haemost; 2015 Jul; 13(7):1293-300. PubMed ID: 25944555
[TBL] [Abstract][Full Text] [Related]
14. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.
Shapiro AD; Angchaisuksiri P; Astermark J; Benson G; Castaman G; Chowdary P; Eichler H; Jiménez-Yuste V; Kavakli K; Matsushita T; Poulsen LH; Wheeler AP; Young G; Zupancic-Salek S; Oldenburg J
Blood; 2019 Nov; 134(22):1973-1982. PubMed ID: 31444162
[TBL] [Abstract][Full Text] [Related]
16. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
[TBL] [Abstract][Full Text] [Related]
17. Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B.
Tardy-Poncet B; Montmartin A; Chambost H; Lienhart A; Frotscher B; Morange PE; Falaise C; Collange F; Dargaud Y; Toussaint-Hacquard M; Ardillon L; Wibaut B; Jeanpierre E; Nguyen P; Volot F; Tardy B
Haemophilia; 2024 May; 30(3):693-701. PubMed ID: 38650319
[TBL] [Abstract][Full Text] [Related]
18. Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody.
Crépin R; Morin C; Montmartin A; Tardy-Poncet B; Chelle P
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):563-580. PubMed ID: 33846873
[TBL] [Abstract][Full Text] [Related]
19. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma.
Siegemund T; Petros S; Siegemund A; Scholz U; Engelmann L
Thromb Haemost; 2003 Nov; 90(5):781-6. PubMed ID: 14597971
[TBL] [Abstract][Full Text] [Related]
20. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.
Knappe S; Gorczyca ME; Jilma B; Derhaschnig U; Hartmann R; Palige M; Scheiflinger F; Dockal M
Thromb Haemost; 2013 Mar; 109(3):450-7. PubMed ID: 23348798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
